Clinical trial
A Multicenter, Randomized, Open-Label, Blinded-Endpoint Phase II Study of Tolecizumab (a PCSK9 Inhibitor) Enhancing Chemoimmunotherapy as Neoadjuvant Treatment for Patients With pMMR/MSS Locally Advanced Colon Adenocarcinoma (TRIUNITE-08)
NCT07468630 is registered in ClinicalTrials.gov with Daping Hospital and the Research Institute of Surgery of the Third Military Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Open-Label, Blinded-Endpoint Phase II Study of Tolecizumab (a PCSK9 Inhibitor) Enhancing Chemoimmunotherapy as Neoadjuvant Treatment for Patients With pMMR/MSS Locally Advanced Colon Adenocarcinoma (TRIUNITE-08)
- Lead sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- April 10, 2026
- Completion date
- December 31, 2028
- Enrollment
- 106 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
colon adenocarcinoma